Aratana therapeutics, inc. (PETX)
CashFlow / Quarterly
Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities
Net loss

-6,787

-8,634

8,833

-6,373

-8,548

-15,598

-8,920

-10,380

-12,612

-23,333

-13,371

21,196

-18,067

-

-

-

-8,774

-

-

-

-

Net income (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,152

Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,000

0

500

657

Stock-based compensation expense

2,306

1,078

1,194

1,257

1,384

1,661

1,799

1,844

1,814

1,940

2,087

2,196

2,253

2,103

2,100

2,029

2,360

1,889

1,541

1,467

2,233

Depreciation and amortization expense

261

247

247

247

249

234

323

213

392

253

245

249

244

244

540

536

520

159

701

617

566

Gain on sale of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,864

1,010

-

-

-

-

Non-cash interest expense

-

600

139

139

140

143

132

118

119

120

119

119

120

99

10

10

10

11

10

10

10

Change in fair value of contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-1,248

50

-33

-166

16

Change in fair value of derivative instruments

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

316

958

667

17

28

-247

Deferred tax benefit

-

-

-

-

-

-

-

-

-

-

-

-

-

-309

-758

-360

-271

120

-601

-335

-627

Changes in operating assets and liabilities:
Accounts receivable, net

2,655

-17,373

16,742

397

32

-7,030

4,543

1,354

3,452

72

-2

6

-49

-73

-14

33

-227

276

-290

241

-125

Inventories

-597

-875

-581

1,579

376

4,882

2,474

-2,094

-2,075

9,189

3,009

1,765

1,047

133

291

237

218

224

79

-1

70

Prepaid expenses and other current assets

-649

89

810

-354

-360

-150

-4,767

5,288

-706

-170

840

-305

406

-

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-140

197

-

-129

88

378

Other assets

-91

-176

-2

0

-10

12

-67

0

-33

18

4

0

-17

-

-

-

-

4

1

-1

41

Accounts payable

58

254

-489

-744

-5,561

4,095

1,502

687

-6,222

2,470

-2,162

896

4,978

157

-487

-417

630

-380

913

-391

-1,285

Accrued expenses and other liabilities

-11

-605

1,796

573

-840

-243

-1,653

580

-1,289

2,571

-1,111

2,174

-1,550

656

-74

680

-77

335

397

254

-504

Net cash used in operating activities

-5,491

12,507

-4,366

-6,188

-13,214

343

-8,606

-11,486

-18,436

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-56

-8

Net cash provided by (used in) operating activities

-

-

-

-

-

-

-

-

-

-

-

36,696

-13,409

-

-10,298

-8,800

-9,006

-9,428

-6,816

-7,733

-8,211

Cash flows from investing activities
Purchase of investments

496

-

-

-

498

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of investments

-1,240

-

-

-

-747

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Milestone payments for intangible assets

-

-

-

-

-

3,000

0

0

3,000

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment, net

-

-

-

-

-

-

-

-

-

47

6

13

6

389

758

1,049

49

-163

388

179

67

Cash paid for acquisitions, net of cash received

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-219

12,294

Proceeds from sales of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

5,956

1,500

-

-

-

-

Purchase of investments

-

-

-

-

-

747

996

1,494

494

996

1,494

30,947

196,399

457,847

687,747

712,000

193,000

311,249

59,000

0

1,200

Proceeds from maturities of investments

-

-

-

-

-

1,494

996

494

996

1,494

747

89,199

196,847

457,647

699,500

698,249

224,000

274,470

9,983

741

1,476

Net cash provided by investing activities

744

496

-992

-246

249

-2,238

-5

-1,011

-2,498

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of derivative instruments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

643

Purchase of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,000

0

500

657

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

58,239

442

-

10,995

-8,844

32,451

-37,616

-49,405

281

-13,385

Cash flows from financing activities
Taxes paid for awards vested under equity incentive plans

150

13

9

4

42

8

0

0

11

-

-

-

-

-

-

-

-

-

-

-

-

Repurchase of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

7

998

76

Proceeds from stock option exercises

27

3

0

7

5

90

5

146

6

-

-

-

-

-

-

-

-

28

152

0

45

Proceeds from issuance of common stock, net of commissions and underwriter fees

-

-

4,884

3,896

15,614

-

1

26,239

1,223

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from public offering, net of commission

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

44,996

0

92,224

Payments for common stock issuance costs

-

7

21

86

57

0

0

278

67

-

-

-

-

-

-

-

-

14

408

4

1,727

Payments on loans payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

106

-18,173

Cash paid for contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

3,000

0

0

156

15,010

Payments on loans payable

-

-

4,500

4,500

3,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

264

47

-3,000

14

44,733

-1,052

57,283

Net cash provided by (used in) financing activities

-123

-25,860

354

-687

12,520

-83

-1,372

23,775

1,151

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate on cash

-

3

0

-16

4

-3

9

16

5

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate on cash

-

-

-

-

-

-

-

-

-

-

17

9

26

-20

-31

24

-104

67

3

32

-28

Net decrease in cash, cash equivalents and restricted cash

-4,870

-12,854

-5,004

-7,137

-441

-1,981

-9,974

11,294

-19,778

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-7,912

94,945

-12,941

-

930

-17,573

20,341

-46,963

-11,485

-8,472

35,659

Supplemental disclosure of cash flow information
Cash paid for interest

-

1,954

602

681

728

729

738

766

733

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

721

-

213

209

206

358

171

27

386

Supplemental disclosure of noncash investing and financing activities:
Unpaid common stock issuance costs included in accounts payable

-

-

-

-

38

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Milestone capitalized as an intangible asset included in accounts payable

2,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-